← Back to Clinical Trials
Recruiting Phase 4 NCT05858619
Molecular Signatures of Cutaneous Dupilumab Response
Trial Parameters
Condition Atopic Dermatitis
Sponsor University of California, San Francisco
Study Type INTERVENTIONAL
Phase Phase 4
Enrollment 15
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2023-02-01
Completion 2026-02-01
Interventions
Dupilumab
Brief Summary
This study examines the effect of IL4RA blockade with dupilumab on the immune cells of atopic dermatitis skin lesions.
Eligibility Criteria
Inclusion Criteria: 1. 18 years of age or older 2. atopic dermatitis with a EASI (Eczema Area and Severity Index (EASI)) score of ≥7 Exclusion Criteria: 1. Known pregnancy 2. Known immunodeficiencies 3. Known parasitic infection -
Related Trials
NCT07467564
The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Se
View Trial →
NCT06004986
DUPIlumab Dose REDUCtion in Patients With Controlled Atopic Eczema
View Trial →
NCT05938478
Monitoring Pregnancy and Infant Outcomes Following Tralokinumab Exposure During Pregnancy in the US
View Trial →